Home » Pfizer to Buy OTC Rights to Nexium for $250 Million Upfront
Pfizer to Buy OTC Rights to Nexium for $250 Million Upfront
Pfizer has agreed to acquire rights to market AstraZeneca’s popular heartburn drug Nexium for OTC use, paying $250 million up front as well as milestone and royalty payments.
The Wall Street Journal
The Wall Street Journal
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May